Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

biontech manufacturing gmbh - combinaţie - concentrat pentru dispersie injectabilă - 30 mcg/doză

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

johnson & johnson srl - trabectedinum - liofilizat pentru concentrat pentru solutie perfuzabila - 1 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

baxter holding b.v. - doxorubicină clorhidrat - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - agenți antineoplazici - caelyx lipozomală polietilenglicată este indicat:ca monoterapie la pacienții cu cancer de sân metastatic, în cazul în care există un risc cardiac crescut;pentru tratamentul cancerului ovarian avansat la femeile care nu au reușit o primă linie de chimioterapie pe bază de platină regim;în asociere cu bortezomib pentru tratamentul mielomului multiplu progresiv la pacienții care au primit cel puțin un tratament anterior și care au suferit deja sau sunt improprii pentru transplant de măduvă osoasă;pentru tratamentul sida legate de sarcom kaposi (sk) la pacienții cu număr mic de celule cd4 (.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haupt pharma muenster gmbh - germania - anastrozolum - compr. film. - 1mg - antagonisti hormonali si substante inrudite inhibitori enzimatici

Uniunea Europeană - română - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - agenți antineoplazici - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Uniunea Europeană - română - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicină clorhidrat - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agenți antineoplazici - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Uniunea Europeană - română - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agenți antineoplazici - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

stada arzneimittel ag - germania - olanzapinum - compr. - 0,088mg - agenti dopaminergici agonisti dopaminergici

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

stada arzneimittel ag - germania - olanzapinum - compr. - 0,18mg - agenti dopaminergici agonisti dopaminergici

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

stada arzneimittel ag - germania - olanzapinum - compr. - 0,7mg - agenti dopaminergici agonisti dopaminergici